SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CCS648 who wrote (867)2/10/2025 2:57:16 PM
From: End2War2 Recommendations

Recommended By
bobbseytwins2001
rodneyh07

   of 1229
 
PSS seems convinced he understands Anktiva's MOA.

I like this ending:
" We have initiated this trial where before you get the radiotherapy, we will give Anktiva to rescue the lymphocytes. We will also give an adeno PSA that generates memory T cells [for] prostate cancer. If you want to add radiation to that, you do the radiation. We can avoid ADT and monitor the patient's PSA. What I will be showing at the AUA is that we've initiated that now as a full trial. [There] is very exciting data, which we will share."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News